Pfizer CEO plans to meet activist investor Starboard Value, FT reports
Adds details in paragraph 2, background throughout
Oct 8 (Reuters) -Pfizer PFE.N CEO Albert Bourla plans to meet key executives of activist hedge fund Starboard Value next week, the Financial Times reported on Tuesday, citing people familiar with the matter.
Bourla and Shantanu Narayen, Pfizer's lead independent director and Adobe Systems ADBE.O CEO, will hold talks with Starboard chief executive Jeff Smith and Patrick Sullivan, who runs its healthcare investments, the report said.
Reuters reported on Sunday, citing sources, that Starboard Value had taken a stake of about $1 billion in Pfizer and wanted the drugmaker to make changes to turn its performance around.
Starboard approached Ian Read, a former Pfizer CEO, and Frank D'Amelio, who served as CFO until 2021, who expressed interest in helping the activist investor, sources told Reuters.
Pfizer declined to comment, while Starboard Value did not immediately respond to a Reuters request for comment.
CEO Bourla, who took the helm in 2019, has been trying to turnaround Pfizer after its slump from pandemic-era highs, hurt by shrinking sales of its COVID products.
Bourla spent some $70 billion since 2020 on acquisitions, including the $43 billion buyout of Seagen last year, while launching cost-saving initiatives.
The drugmaker has struggled to find a product that would make up for the lost revenue from its COVID vaccine and pill.
It had a weaker-than-expected launch of its respiratory syncytial virus (RSV) vaccine and disappointing clinical data from an obesity pill it was developing.
Starboard's exact recommendations for Pfizer could not immediately be ascertained, the FT report added.
Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
